vs
Side-by-side financial comparison of BayCom Corp (BCML) and ROCKWELL MEDICAL, INC. (RMTI). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $18.3M, roughly 1.4× ROCKWELL MEDICAL, INC.). BayCom Corp runs the higher net margin — 26.5% vs -3.0%, a 29.5% gap on every dollar of revenue. On growth, BayCom Corp posted the faster year-over-year revenue change (9.4% vs -25.6%). BayCom Corp produced more free cash flow last quarter ($30.1M vs $2.2M). Over the past eight quarters, BayCom Corp's revenue compounded faster (2.9% CAGR vs -10.1%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
Rockwell Medical Inc. is a publicly traded pharmaceutical company based in Wixom, Michigan and founded in 1996 that focuses on development and commercialization of treatments against diseases such as end-stage renal disease (ESRD) and chronic kidney disease (CKD).
BCML vs RMTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $18.3M |
| Net Profit | $6.9M | $-554.0K |
| Gross Margin | — | 21.1% |
| Operating Margin | 36.6% | -2.2% |
| Net Margin | 26.5% | -3.0% |
| Revenue YoY | 9.4% | -25.6% |
| Net Profit YoY | 12.1% | 26.7% |
| EPS (diluted) | $0.63 | $-0.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $18.3M | ||
| Q3 25 | $25.7M | $15.9M | ||
| Q2 25 | $24.7M | $16.1M | ||
| Q1 25 | $24.3M | $18.9M | ||
| Q4 24 | $23.7M | $24.7M | ||
| Q3 24 | $25.6M | $28.3M | ||
| Q2 24 | $23.8M | $25.8M | ||
| Q1 24 | $24.5M | $22.7M |
| Q4 25 | $6.9M | $-554.0K | ||
| Q3 25 | $5.0M | $-1.8M | ||
| Q2 25 | $6.4M | $-1.5M | ||
| Q1 25 | $5.7M | $-1.5M | ||
| Q4 24 | $6.1M | $-756.0K | ||
| Q3 24 | $6.0M | $1.7M | ||
| Q2 24 | $5.6M | $343.0K | ||
| Q1 24 | $5.9M | $-1.7M |
| Q4 25 | — | 21.1% | ||
| Q3 25 | — | 14.3% | ||
| Q2 25 | — | 15.6% | ||
| Q1 25 | — | 16.1% | ||
| Q4 24 | — | 14.7% | ||
| Q3 24 | — | 22.0% | ||
| Q2 24 | — | 17.6% | ||
| Q1 24 | — | 13.5% |
| Q4 25 | 36.6% | -2.2% | ||
| Q3 25 | 26.3% | -9.9% | ||
| Q2 25 | 35.3% | -8.4% | ||
| Q1 25 | 31.6% | -7.2% | ||
| Q4 24 | 34.2% | -2.1% | ||
| Q3 24 | 32.4% | 6.8% | ||
| Q2 24 | 31.9% | 2.0% | ||
| Q1 24 | 33.3% | -5.8% |
| Q4 25 | 26.5% | -3.0% | ||
| Q3 25 | 19.5% | -11.0% | ||
| Q2 25 | 25.8% | -9.3% | ||
| Q1 25 | 23.4% | -8.0% | ||
| Q4 24 | 25.9% | -3.1% | ||
| Q3 24 | 23.5% | 5.9% | ||
| Q2 24 | 23.6% | 1.3% | ||
| Q1 24 | 24.0% | -7.6% |
| Q4 25 | $0.63 | $-0.01 | ||
| Q3 25 | $0.46 | $-0.05 | ||
| Q2 25 | $0.58 | $-0.05 | ||
| Q1 25 | $0.51 | $-0.04 | ||
| Q4 24 | $0.55 | $-0.02 | ||
| Q3 24 | $0.54 | $0.04 | ||
| Q2 24 | $0.50 | $0.01 | ||
| Q1 24 | $0.51 | $-0.06 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $10.7M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $37.0M |
| Total Assets | $2.6B | $57.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.7M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | — | $12.5M | ||
| Q1 25 | — | $11.4M | ||
| Q4 24 | — | $15.7M | ||
| Q3 24 | — | $12.3M | ||
| Q2 24 | — | $11.9M | ||
| Q1 24 | — | $6.6M |
| Q4 25 | $338.6M | $37.0M | ||
| Q3 25 | $334.3M | $37.0M | ||
| Q2 25 | $330.6M | $30.4M | ||
| Q1 25 | $329.3M | $31.5M | ||
| Q4 24 | $324.4M | $32.6M | ||
| Q3 24 | $321.7M | $29.1M | ||
| Q2 24 | $315.3M | $23.5M | ||
| Q1 24 | $314.2M | $20.6M |
| Q4 25 | $2.6B | $57.1M | ||
| Q3 25 | $2.6B | $57.5M | ||
| Q2 25 | $2.6B | $52.6M | ||
| Q1 25 | $2.6B | $54.0M | ||
| Q4 24 | $2.7B | $59.2M | ||
| Q3 24 | $2.6B | $57.1M | ||
| Q2 24 | $2.6B | $53.0M | ||
| Q1 24 | $2.6B | $50.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $2.3M |
| Free Cash FlowOCF − Capex | $30.1M | $2.2M |
| FCF MarginFCF / Revenue | 116.2% | 12.0% |
| Capex IntensityCapex / Revenue | 6.7% | 0.5% |
| Cash ConversionOCF / Net Profit | 4.64× | — |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | $-1.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $2.3M | ||
| Q3 25 | $7.3M | $-1.3M | ||
| Q2 25 | $6.4M | $1.8M | ||
| Q1 25 | $9.3M | $-3.5M | ||
| Q4 24 | $30.4M | $865.0K | ||
| Q3 24 | $9.6M | $4.3M | ||
| Q2 24 | $7.7M | $1.4M | ||
| Q1 24 | $5.1M | $-2.4M |
| Q4 25 | $30.1M | $2.2M | ||
| Q3 25 | $6.2M | $-1.5M | ||
| Q2 25 | $5.6M | $1.7M | ||
| Q1 25 | $9.1M | $-3.5M | ||
| Q4 24 | $28.7M | $470.0K | ||
| Q3 24 | $9.4M | $4.1M | ||
| Q2 24 | $7.4M | $1.2M | ||
| Q1 24 | $3.9M | $-2.5M |
| Q4 25 | 116.2% | 12.0% | ||
| Q3 25 | 24.3% | -9.6% | ||
| Q2 25 | 22.8% | 10.5% | ||
| Q1 25 | 37.6% | -18.8% | ||
| Q4 24 | 121.1% | 1.9% | ||
| Q3 24 | 36.6% | 14.4% | ||
| Q2 24 | 31.2% | 4.5% | ||
| Q1 24 | 16.1% | -11.1% |
| Q4 25 | 6.7% | 0.5% | ||
| Q3 25 | 4.3% | 1.4% | ||
| Q2 25 | 3.0% | 1.0% | ||
| Q1 25 | 0.6% | 0.3% | ||
| Q4 24 | 7.2% | 1.6% | ||
| Q3 24 | 1.0% | 0.7% | ||
| Q2 24 | 1.0% | 1.1% | ||
| Q1 24 | 4.7% | 0.6% |
| Q4 25 | 4.64× | — | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | 2.57× | ||
| Q2 24 | 1.37× | 4.20× | ||
| Q1 24 | 0.86× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
RMTI
| US | $15.9M | 87% |
| Non Us | $2.4M | 13% |
